Cardiome Pharma's ( CRME) shares got a 33% boost after the company reported positive results from a trial involving its proposed heart drug for patients with abnormal heart rhythms. Of 54 patients receiving the drug in trials, 61% finished the study with a normal heart rhythm, compared with 37% of 27 of patients receiving a placebo, the company reported. The drug, dubbed RSD1235, appeared well tolerated among trial patients. Shares were up $2.99 to $11.90. PDL BioPharma's ( PDLI) shares rose after the stock was upgraded by Deutsche Securities to a buy rating from a hold. The stock was up 6.5% to $17.59. In March, the firm downgraded PDL's shares to hold as a result of disappointing first-quarter earnings and a lowered fiscal-year outlook, but "in our view, PDLI shares have now more than over-corrected and represent a compelling valuation opportunity ahead of potentially solid to better-than-expected second-quarter earnings results," wrote Deutsche biotech analyst Jennifer Chao. PDL is slated to report its quarterly earnings on Aug. 3. Shares of WebMD Health ( WBMD) and its parent Emdeon ( HLTH) climbed following an announcement that the companies were awarded a contract from the U.S. Centers for Medicare and Medicaid Services. Under the contract, the companies will conduct feasibility tests to determine how medical-claims data can be used to create a system of electronic personal-health records. WebMD was up 1.7% to $40.56, and Emdeon was adding 1.7% to $12.25. Bayer ( BAY) and its partner Onyx Pharmaceuticals ( ONXX) were up following a weekend announcement that they received European Commission approval for Nexavar in the treatment of advanced kidney cancer. Bayer's shares were gaining 2.2% to $48.43, and Onyx shares tacked on 1 cent to $15.35. Nexavar was approved by the Food and Drug Administration in December. Shares of Biogen Idec ( BIIB) and Elan ( ELN) got a lift following word that the companies have re-released Tysabri for the treatment of relapsing forms of multiple sclerosis.